--- title: "Arcus ends last TIGIT phase 3 as Gilead gives up its three board seats" url: "https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-05" section: "Financings" tickers: "NYSE:RCUS, NASDAQ:GILD, LSE:AZN" source: "https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm" summary: "Arcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of" --- By the aibio.space Arcus desk. Sources - [Arcus Biosciences (SEC Form 8-K exhibit)](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm) - [Arcus Biosciences Form 10-Q, Q2 2026](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000044/rcus-20260630.htm) - [SEC Form 8-K, April 20, 2026](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000021/rcus-20260420.htm) [RCUS](https://aibio.space/companies/arcus-biosciences/) [GILD](https://aibio.space/companies/gilead-sciences/) [AZN](https://aibio.space/companies/astrazeneca/) 2026-08-05 # Arcus ends last TIGIT phase 3 as Gilead gives up its three board seats Tickers [RCUS](https://aibio.space/companies/arcus-biosciences/)[GILD](https://aibio.space/companies/gilead-sciences/)[AZN](https://aibio.space/companies/astrazeneca/) Arcus and AstraZeneca will stop PACIFIC-8 in stage III lung cancer. Second-quarter cash was $775 million, with runway guided to at least the second half of 2028. ## Key facts - **Companies**: Arcus Biosciences, Inc. (NYSE: RCUS), Gilead Sciences, Inc. (NASDAQ: GILD), AstraZeneca PLC (LSE: AZN) - **News type**: Financings - **Primary source**: [Arcus Biosciences (SEC Form 8-K exhibit)](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm) *A meeting room with a long table and a screen. CC0, via rawpixel. The picture shows the field, not the companies named.* Arcus Biosciences said on Aug. 5 that it and AstraZeneca will discontinue [PACIFIC-8](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm), a phase 3 trial of the anti-TIGIT antibody domvanalimab plus durvalumab against durvalumab alone in PD-L1 positive, stage III unresectable non-small cell lung cancer. The decision ends Arcus's late-stage TIGIT work. In the same second-quarter report, Arcus said Gilead Sciences had [given up its three seats on Arcus's board](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm), effective Aug. 5, in connection with the wind-down of the phase 3 trials and what Arcus called a streamlined operating relationship. ## The details PACIFIC-8 was the third domvanalimab phase 3 to end. Arcus said it followed the discontinuations of STAR-221 in upper gastrointestinal cancer and STAR-121 in lung cancer. In April, Arcus said an independent data monitoring committee recommended stopping STAR-121 after a [pre-planned futility analysis](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000021/rcus-20260420.htm). At that analysis, the domvanalimab combination [did not improve overall survival](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000032/a2026q18kexhibit991.htm) compared with pembrolizumab plus chemotherapy. Gilead also chose not to make an option continuation payment, so its option period under the 2020 collaboration [ended on July 14, 2026](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000021/rcus-20260420.htm). Gilead lost option rights to programs including Arcus's CCR6, CD89 and CD40L work but kept time-limited options on AB801, AB598 and a TNF small molecule. Its option on AB102 had expired in the second quarter, the 10-Q says. Gilead remains a large shareholder: the 10-Q says it owned [about 24.7% of Arcus's common stock](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000044/rcus-20260630.htm) at June 30. Quarterly revenue fell to [$41 million from $160 million](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm) a year earlier, when Arcus booked a $143 million catch-up related to Gilead returning etrumadenant. Research and development spending was $113 million, down from $139 million, and the net loss was $91 million. Cash, equivalents and marketable securities were $775 million at June 30, down from $1.0 billion at the end of 2025. ## Context With TIGIT gone, Arcus's plan rests on casdatifan in kidney cancer. The same report listed new collaborations with [Bristol Myers Squibb, Summit Therapeutics and AVEO Oncology](https://s202.q4cdn.com/599190870/files/doc_news/Arcus-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-a-Pipeline-Update-2026.pdf) to test casdatifan combinations, and a $15 million milestone payment due from Taiho in the third quarter tied to PEAK-1 enrollment in Japan. Arcus's second phase 3 asset, the CD73 inhibitor quemliclustat, has results from the PRISM-1 pancreatic cancer trial due in the [first half of 2027](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm). Chief executive Terry Rosen said the company sees ["a clear path to be first-to-market"](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm) in front-line kidney cancer. ## What it means for investors Stopping PACIFIC-8 removes a cost and an overhang. Arcus said it expects R&D costs to [keep falling in the near term](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm) as domvanalimab studies wind down, offset partly by more spending on casdatifan and immunology programs. Full-year GAAP revenue guidance rose to $65 million to $75 million, from $50 million to $65 million in May. Gilead leaving the board loosens a tie that once defined Arcus. The partner still holds [about a quarter of the stock](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000044/rcus-20260630.htm), and a large holder with no board seat is freer to reduce its stake, which is a supply risk for the shares. The company now has one main late-stage bet, so a setback in PEAK-1 would hit harder than it would have when TIGIT and adenosine programs shared the load. ## What to watch Arcus guided to ending 2026 with [about $600 million in cash](https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/a2026q28kexhibit991.htm), to completing PEAK-1 enrollment and to starting the PEAK-20 first-line trial by year-end. New ARC-20 casdatifan data were promised for the second half of 2026. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story RCUS Arcus Biosciences, Inc. NYSE · United States Open the desk GILD Gilead Sciences, Inc. NASDAQ · United States Open the desk AZN AstraZeneca PLC LSE · United Kingdom Open the desk ## More from the Arcus desk Financings ### [Arcus raises $250 million at $17.50 a share a day after kidney cancer data](https://aibio.space/news/arcus-raises-250-million-17-50-share-day-after-kidney-cancer-data/) Oct 21, 2026 Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 Debt Financing ### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/) Oct 30, 2026 --- Source page: https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Arcus ends last TIGIT phase 3 as Gilead gives up its three board seats", 2026-08-05, https://aibio.space/news/arcus-ends-last-tigit-phase-3-gilead-gives-up-three-board-seats/